Estrogen plus progestin and risk of benign proliferative breast disease

Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Norman L. Lasser, Anne McTiernan, Robert S. Schenken, Mindy S. Ginsberg, Sylvia Wassertheil-Smoller, David L. Page

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74% increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95% confidence interval (CI), 1.35-2.25]. For benign proliferative breast disease without atypia the hazard ratio was 2.00 (95% CI, 1.50-2.66), while for atypical hyperplasia it was 0.76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease.

Original languageEnglish (US)
Pages (from-to)2337-2343
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume17
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

Breast Diseases
Progestins
Estrogens
Conjugated (USP) Estrogens
Women's Health
Confidence Intervals
Breast
Placebos
Breast Neoplasms
Biopsy
Medroxyprogesterone Acetate
Hormone Replacement Therapy
Hyperplasia
Progesterone
Epithelium
Randomized Controlled Trials

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Estrogen plus progestin and risk of benign proliferative breast disease. / Rohan, Thomas E.; Negassa, Abdissa; Chlebowski, Rowan T.; Lasser, Norman L.; McTiernan, Anne; Schenken, Robert S.; Ginsberg, Mindy S.; Wassertheil-Smoller, Sylvia; Page, David L.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 17, No. 9, 09.2008, p. 2337-2343.

Research output: Contribution to journalArticle

Rohan, TE, Negassa, A, Chlebowski, RT, Lasser, NL, McTiernan, A, Schenken, RS, Ginsberg, MS, Wassertheil-Smoller, S & Page, DL 2008, 'Estrogen plus progestin and risk of benign proliferative breast disease', Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 9, pp. 2337-2343. https://doi.org/10.1158/1055-9965.EPI-08-0380
Rohan, Thomas E. ; Negassa, Abdissa ; Chlebowski, Rowan T. ; Lasser, Norman L. ; McTiernan, Anne ; Schenken, Robert S. ; Ginsberg, Mindy S. ; Wassertheil-Smoller, Sylvia ; Page, David L. / Estrogen plus progestin and risk of benign proliferative breast disease. In: Cancer Epidemiology Biomarkers and Prevention. 2008 ; Vol. 17, No. 9. pp. 2337-2343.
@article{cffba4ccbc8b46c8b8e7e4267bab79bd,
title = "Estrogen plus progestin and risk of benign proliferative breast disease",
abstract = "Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74{\%} increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95{\%} confidence interval (CI), 1.35-2.25]. For benign proliferative breast disease without atypia the hazard ratio was 2.00 (95{\%} CI, 1.50-2.66), while for atypical hyperplasia it was 0.76 (95{\%} CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease.",
author = "Rohan, {Thomas E.} and Abdissa Negassa and Chlebowski, {Rowan T.} and Lasser, {Norman L.} and Anne McTiernan and Schenken, {Robert S.} and Ginsberg, {Mindy S.} and Sylvia Wassertheil-Smoller and Page, {David L.}",
year = "2008",
month = "9",
doi = "10.1158/1055-9965.EPI-08-0380",
language = "English (US)",
volume = "17",
pages = "2337--2343",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Estrogen plus progestin and risk of benign proliferative breast disease

AU - Rohan, Thomas E.

AU - Negassa, Abdissa

AU - Chlebowski, Rowan T.

AU - Lasser, Norman L.

AU - McTiernan, Anne

AU - Schenken, Robert S.

AU - Ginsberg, Mindy S.

AU - Wassertheil-Smoller, Sylvia

AU - Page, David L.

PY - 2008/9

Y1 - 2008/9

N2 - Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74% increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95% confidence interval (CI), 1.35-2.25]. For benign proliferative breast disease without atypia the hazard ratio was 2.00 (95% CI, 1.50-2.66), while for atypical hyperplasia it was 0.76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease.

AB - Women with benign proliferative breast disease are at increased risk of subsequent breast cancer. Estrogens and progesterone exert proliferative effects on mammary epithelium, and combined hormone replacement therapy has been associated with increased breast cancer risk. We tested the effect of conjugated equine estrogen plus progestin on the risk of benign proliferative breast disease in the Women's Health Initiative (WHI) randomized controlled trial. In the WHI trial of estrogen plus progestin, 16,608 postmenopausal women were randomly assigned either to 0.625 mg/day of conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone acetate or to placebo. Baseline and annual breast exams and mammograms were required. The trial was terminated early (average follow-up, 5.5 years). We identified women who had had a biopsy for benign breast disease, and subjected histologic sections from the biopsies to standardized review. Overall, 178 incident cases of benign proliferative breast disease were ascertained in the estrogen plus progestin group and 99 in the placebo group. The use of estrogen plus progestin was associated with a 74% increase in the risk of benign proliferative breast disease [hazard ratio, 1.74; 95% confidence interval (CI), 1.35-2.25]. For benign proliferative breast disease without atypia the hazard ratio was 2.00 (95% CI, 1.50-2.66), while for atypical hyperplasia it was 0.76 (95% CI, 0.38-1.52). The risk varied little by levels of baseline characteristics. The results of this study suggest that the use of estrogen plus progestin may increase the risk of benign proliferative breast disease.

UR - http://www.scopus.com/inward/record.url?scp=53349117967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53349117967&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-08-0380

DO - 10.1158/1055-9965.EPI-08-0380

M3 - Article

C2 - 18725513

AN - SCOPUS:53349117967

VL - 17

SP - 2337

EP - 2343

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 9

ER -